Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Team changes

07/06/2021 | 02:02am EDT
Arix Bioscience PLC (ARIX) 
Team changes 
06-Jul-2021 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
Arix Bioscience plc 
Team changes 
LONDON, 06 July 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company 
focused on investing and building breakthrough biotech companies, today announces that Mark Chin will be re-joining the 
Arix investment team as a Managing Director effective immediately. 
Mark previously spent four years at Arix from 2016 to 2020 as an Investment Director. Mark sourced and led deals in key 
Arix portfolio companies, including: VelosBio (acquired by Merck for USD2.75bn), Amplyx Pharmaceuticals (acquired by 
Pfizer), Aura Biosciences, Harpoon Therapeutics (Nasdaq IPO) and Imara (Nasdaq IPO). He has extensive venture capital 
expertise in early to late stage investing and significant experience as a board member, of both private and public 
companies in the US and Europe. Since leaving Arix in 2020, Mark has remained a director of Harpoon Therapeutics, Inc. 
(Nasdaq: HARP), Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics plc (Nasdaq: ITRM). Mark is based in New York and 
will work to source and evaluate new investment opportunities and support existing venture investments through to exit. 
Dr. Christian Schetter, Managing Director, has resigned from the investment team and will leave the Company on 31 
August 2021. Dr. John Cassidy, Principal, had previously resigned from the investment team and will leave the Company 
on 30 July 2021. Following the changes announced on 30 April 2021, the Board continues to develop the Company's 
strategy and evaluate the appropriate team structure. The Board will work closely with Mark Chin to rebuild the 
Company's investment team, adding new talent to deploy investment capital and manage the Company's existing portfolio. 
After five years at Arix, Marcus Karia, Group Finance Director, will leave the Company later this year to pursue other 
opportunities. Marcus will continue in his role until a search for his successor is completed. 
Robert Lyne, Interim CEO of Arix, commented: "I am very pleased to welcome Mark back to Arix. Mark is a talented 
investor and has played an instrumental role in the development of Arix, identifying and leading a number of high 
quality investments, which have made a significant contribution to the strong performance across Arix's portfolio. Mark 
will work closely with the Board to determine Arix's future investment strategy and will play a pivotal role in 
building the investment team and shaping the Company's future. 
"On behalf of the Company I would like to thank Christian, John and Marcus for their valuable contribution to Arix. We 
wish them all the best for the future." 
Mark Chin, Managing Director at Arix, added: "Biotech is now recognised as one the most important sectors to society: 
the vaccine response to the pandemic and recent breakthroughs in oncology and other diseases underscore its disruptive 
potential. Having seen first-hand the novel technologies Arix has fueled, and with the significant capital available to 
us, I am excited to help identify and build the next generation of innovative biotech companies based on cutting-edge 
science and world-class leadership." 
Peregrine Moncreiffe, Chairman of Arix, commented: "The Board is determined to optimise Arix's contribution to the 
biotech sector in Europe and the US and believes that its reconstituted investment team will generate superior 
risk-adjusted returns for our shareholders." 
For more information on Arix, please contact: 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
+44 (0)20 7290 1072 
Optimum Strategic Communications 
Mary Clark, Manel Mateus 
+44 (0)20 3922 1906 
About Arix Bioscience plc 
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech 
companies around cutting-edge advances in life sciences. 
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate 
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth 
phase of our industry to a broader range of investors. www.arixbioscience.com 
ISIN:           GB00BD045071 
Category Code:  MSCH 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   115436 
EQS News ID:    1215445 
End of Announcement  EQS News Service 
Image link: 

(END) Dow Jones Newswires

July 06, 2021 02:01 ET (06:01 GMT)

09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
09/20ARIX BIOSCIENCE PLC(LSE : ARIX) added to S&P Global BMI Index
09/03VC DAILY : Question: What Is Driving Startup -2-
09/02ARIX BIOSCIENCE : To Invest $11 Million In Disc Medicine
09/02Arix Bioscience participates in USD90 million Series B financing for Disc Medicine
09/02Disc Medicine, Inc. announced that it has received $90 million in funding from a group ..
09/01Total Voting Rights
08/31Transaction in own shares
08/16Transaction in own shares
08/16Director/PDMR Shareholding
More news
Sales 2021 0,50 M 0,68 M 0,68 M
Net income 2021 37,7 M 51,5 M 51,5 M
Net cash 2021 146 M 199 M 199 M
P/E ratio 2021 5,54x
Yield 2021 -
Capitalization 200 M 273 M 273 M
EV / Sales 2021 108x
EV / Sales 2022 88,4x
Nbr of Employees 12
Free-Float 72,2%
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 160,00 GBX
Average target price 221,50 GBX
Spread / Average Target 38,4%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
INVESTOR AB (PUBL)32.08%70 090
HAL TRUST32.13%15 483
LIFCO AB (PUBL)61.60%13 384